Andrew Miller

Company: Karuna Therapeutics

Job title: Founder & President, Research & Development

Seminars:

Reviewing the Journey of Cobenfy So Far & Future Directions for its Applications in Indications Beyond Schizophrenia 9:30 am

Spotlighting the novel mechanism of action of Cobenfy and its selective muscarinic activation in the brain Demonstrating efficacy and safety in the ADEPT-2 Phase 3 Trial for Cobenfy in Alzheimer’s disease psychosis What are the opportunities for Cobenfy to be investigated for the treatment of psychosis in other dementias, bipolar, autism, and more?Read more

day: Day One